Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents		$ 62,001	$ 32,585
Marketable equity securities		6,745	8,977
Trade accounts and grants receivable, net		326	4
Prepaid expenses and other current assets		2,505	2,433
Total current assets		71,577	43,999
NONCURRENT ASSETS
Property and equipment, net (Notes 5 and 14)		5,008	5,630
Deposits and other long-term assets		610	616
Goodwill	[1]	10,672	10,672
Intangible assets, net		46,887	47,032
TOTAL ASSETS		134,754	107,949
CURRENT LIABILITIES
Accounts payable and accrued liabilities		5,348	6,813
Lease liabilities, current portion (Note 14)		790	746
Financing lease, current portion (Note 14)		17	16
Deferred revenues		613	193
Liability classified warrants, current portion			1
Total current liabilities		6,768	7,769
LONG-TERM LIABILITIES
Deferred tax liability		1,907	2,076
Lease liability, net of current portion (Note 14)		2,078	2,514
Financing lease, net of current portion (Note 14)		16	26
Liability classified warrants, net of current portion		384	437
TOTAL LIABILITIES		11,153	12,822
Commitments and contingencies (Note 14)
SHAREHOLDERS’ EQUITY
Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of June 30, 2021 and December 31, 2020
Common shares, no par value, 250,000 shares authorized; 167,037 and 153,096 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		428,046	393,944
Accumulated other comprehensive loss		(3,051)	(3,667)
Accumulated deficit		(300,282)	(294,078)
Lineage Cell Therapeutics, Inc. shareholders’ equity		124,713	96,199
Noncontrolling deficit		(1,112)	(1,072)
Total shareholders’ equity		123,601	95,127
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$ 134,754	$ 107,949

[1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger.